Pluristem Therapeutics to Present at the bioLOGIC Conference
NEW YORK--(BUSINESS WIRE)--Sep 15, 2008 - Pluristem Therapeutics Inc. (Nasdaq:PSTI)(DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that Zami Aberman, President & CEO of the Company, will present at the bioLOGIC Europe 2008 conference on Tuesday, September 16, 2008 at 11:15 a.m. Central European Time at the Crowne Plaza Hotel, Geneva, Switzerland.
The title of Mr. Aberman's presentation is: "Challenges for small and medium biotechs in bringing biological cell therapy products to market". The presentation will include Pluristem Therapeutics' strategic direction, market positioning, updates on clinical trials and new studies regarding the potential of its PLX (PLacental eXpanded) cells.
Mr. Abermam will update on recently obtained results of PLX-PAD pre-clinical efficacy studies showing impressive new vessel formation, indicating that PLX-PAD may bring hope to millions of people suffering from complications of diabetes, Buerger's Disease and smoking where insufficient blood flow to their lower legs places them at risk of amputation.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells' efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-IBD, targeting Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
See our product animation on YouTube: http://www.youtube.com/watch?v=QzAANdeg0b0
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that recently obtained results of PLX-PAD pre-clinical efficacy studies show impressive new vessel formation and indicate that PLX-PAD may bring hope to millions of people suffering from complications of diabetes, Buerger's Disease and smoking where insufficient blood flow to their lower legs places them at risk of amputation, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: failure to obtain required regulatory approvals, changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Pluristem Therapeutics Inc.
William Prather RPh, MD, 303-883-4954 (Investor Contact)
Sr. VP Corporate Development
Posted: September 2008